chr19-11003080-G-A
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 1P and 6B. PP2BP4_ModerateBS2
The NM_003072.5(SMARCA4):c.1864G>A(p.Val622Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000744 in 1,613,964 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_003072.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCA4 | NM_001387283.1 | c.1864G>A | p.Val622Met | missense_variant | 12/36 | ENST00000646693.2 | NP_001374212.1 | |
SMARCA4 | NM_003072.5 | c.1864G>A | p.Val622Met | missense_variant | 12/35 | ENST00000344626.10 | NP_003063.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA4 | ENST00000646693.2 | c.1864G>A | p.Val622Met | missense_variant | 12/36 | NM_001387283.1 | ENSP00000495368.1 | |||
SMARCA4 | ENST00000344626.10 | c.1864G>A | p.Val622Met | missense_variant | 12/35 | 1 | NM_003072.5 | ENSP00000343896.4 | ||
SMARCA4 | ENST00000643549.1 | c.1864G>A | p.Val622Met | missense_variant | 12/35 | ENSP00000493975.1 | ||||
SMARCA4 | ENST00000541122.6 | c.1864G>A | p.Val622Met | missense_variant | 13/35 | 5 | ENSP00000445036.2 | |||
SMARCA4 | ENST00000643296.1 | c.1864G>A | p.Val622Met | missense_variant | 12/34 | ENSP00000496635.1 | ||||
SMARCA4 | ENST00000644737.1 | c.1864G>A | p.Val622Met | missense_variant | 12/34 | ENSP00000495548.1 | ||||
SMARCA4 | ENST00000589677.5 | c.1864G>A | p.Val622Met | missense_variant | 13/35 | 5 | ENSP00000464778.1 | |||
SMARCA4 | ENST00000643995.1 | c.1276G>A | p.Val426Met | missense_variant | 9/32 | ENSP00000496004.1 | ||||
SMARCA4 | ENST00000644963.1 | c.508G>A | p.Val170Met | missense_variant | 5/28 | ENSP00000495599.1 | ||||
SMARCA4 | ENST00000644065.1 | c.589G>A | p.Val197Met | missense_variant | 5/27 | ENSP00000493615.1 | ||||
SMARCA4 | ENST00000642350.1 | c.349G>A | p.Val117Met | missense_variant | 4/27 | ENSP00000495355.1 | ||||
SMARCA4 | ENST00000643857.1 | c.217G>A | p.Val73Met | missense_variant | 3/25 | ENSP00000494159.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152160Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251458Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135898
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461804Hom.: 0 Cov.: 33 AF XY: 0.00000550 AC XY: 4AN XY: 727202
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152160Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74330
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 04, 2023 | This variant is present in population databases (rs745382051, gnomAD 0.006%). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 622 of the SMARCA4 protein (p.Val622Met). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 470264). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SMARCA4 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Hereditary cancer-predisposing syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 13, 2024 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at